Generation Bio Co. (NASDAQ:GBIO) Director Charles A. Rowland, Jr. Purchases 17,147 Shares of Stock

Generation Bio Co. (NASDAQ:GBIOGet Rating) Director Charles A. Rowland, Jr. purchased 17,147 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The stock was acquired at an average price of $5.41 per share, for a total transaction of $92,765.27. Following the completion of the purchase, the director now owns 142,566 shares of the company’s stock, valued at $771,282.06. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Generation Bio Stock Performance

Shares of GBIO stock opened at $5.21 on Tuesday. The stock has a fifty day moving average price of $6.37 and a 200 day moving average price of $6.39. The stock has a market cap of $307.45 million, a PE ratio of -2.20 and a beta of 1.96. Generation Bio Co. has a 1 year low of $3.96 and a 1 year high of $26.70.

Generation Bio (NASDAQ:GBIOGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.03). As a group, equities research analysts predict that Generation Bio Co. will post -2.63 earnings per share for the current year.

Hedge Funds Weigh In On Generation Bio

A number of institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its holdings in shares of Generation Bio by 1.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 8,931,613 shares of the company’s stock worth $58,591,000 after acquiring an additional 167,922 shares during the last quarter. State Street Corp raised its holdings in shares of Generation Bio by 6.5% in the second quarter. State Street Corp now owns 914,928 shares of the company’s stock worth $6,002,000 after acquiring an additional 55,992 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Generation Bio by 17.5% in the first quarter. JPMorgan Chase & Co. now owns 660,275 shares of the company’s stock worth $4,847,000 after acquiring an additional 98,270 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Generation Bio by 2.1% in the second quarter. Northern Trust Corp now owns 412,585 shares of the company’s stock worth $2,707,000 after acquiring an additional 8,409 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Generation Bio by 296.0% in the second quarter. Renaissance Technologies LLC now owns 287,129 shares of the company’s stock worth $1,884,000 after acquiring an additional 214,629 shares during the last quarter. 93.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on GBIO. JMP Securities lifted their price target on Generation Bio from $10.00 to $11.00 and gave the company a “market outperform” rating in a research note on Monday, August 8th. Wedbush restated an “outperform” rating and issued a $24.00 price target on shares of Generation Bio in a research note on Friday, August 5th. Finally, Needham & Company LLC decreased their price target on Generation Bio from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Generation Bio Company Profile

(Get Rating)

Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.

Read More

Insider Buying and Selling by Quarter for Generation Bio (NASDAQ:GBIO)

Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.